DOI: https://doi.org/10.14710/jbtr.v7i3.11909

The Differences of Lipoprotein-Associated Phospholipase A2, Apolipoprotein B and Low Density Lipoprotein In Obese and Lean Men

Faculty of Medicine, Universitas Diponegoro, Indonesia

Received: 31 Jul 2021; Revised: 1 Nov 2021; Accepted: 9 Dec 2021; Available online: 31 Dec 2021; Published: 31 Dec 2021.
Open Access Copyright (c) 2021 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to cite (Vancouver): Yuliana Y, Adipireno P, Limijadi EKS, Widyastiti NS, Retnoningrum D. The Differences of Lipoprotein-Associated Phospholipase A2, Apolipoprotein B and Low Density Lipoprotein In Obese and Lean Men. Journal of Biomedicine and Translational Research [Online]. 2021 Dec;7(3):111-115. https://doi.org/10.14710/jbtr.v7i3.11909.
Citation Format:
Abstract
ABSTRACT

Background: An increase in fat accumulation in obesity has been suggested to link with an increase in inflammation. This inflammation may be associated with an elevated of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Apolipoprotein B (Apo B), and Low-Density Lipoprotein (LDL), thereby associated with the risk of atherosclerosis.

Objective: To investigate the differences between Lp-PLA2, Apo B, and LDL levels in obese and lean men.

Methods: A cross-sectional study was conducted on 74 men (obese and lean) at the Faculty of Medicine, Diponegoro University, Indonesia, in 2020. The concentration of LDL was measured using the homogenous enzymatic colourimetric method, whereas the levels of Lp-PLA2 and Apo B were determined using the ELISA method. Data were analyzed using an Independent t-test, setting statistical significance at p <0.05.

Results: This study showed that Lp-PLA2 levels were significantly different between obese and lean men (p = 0.039). Furthermore, LDL levels were also significantly different between obese and lean men (p = 0.002). However, we did not find any differences in Apo B between obese and lean men (p = 0.640).

Conclusion: Lp-PLA2 and LDL levels were slightly higher in obese compared to lean men, but no difference of Apo B.

 

Fulltext View|Download
Keywords: Lp-PLA2; Apo B; LDL; obesity; normoweight.

Article Metrics:

Article Info
Section: Original Research Articles
Language : EN
Recent articles
Therapeutic Effect of Red Spinach (Amaranthus tricolor L.) Extract on Pancreatic MDA Levels Rats (Rattus norvegicus) Exposed to MLD-STZ The Effectivity of Thymus vulgaris Extract on IL-1 Level and Bacterial Count in The Heart of Balb-c Mice Infected with MRSA The Effectivity of Parsley (Petroselinum crispum) Extract on The Growth Inhibition of Candida Albicans Subacute Spinal Subdural Hematoma in One-Year Old Boy Due to Severe Hemophilia A Melatonin, A Promising Therapeutic for Diabetes Mellitus and Its Complications: A Narrative Review More recent articles
  1. Lilyasari O. Tinjauan Pustaka Hipertensi Dengan Obesitas : Adakah Peran Endotelin-1. J Kardiol Indones. 2007;28(6):460–75
  2. Ramachandran, Ambady & Snehalatha C. Rising Burden of Obesity in Asia. Journal of Obesity. 2010:1-8
  3. Kandinasti S, Farapti. Obesity: Is It Important to Concern about Food Intake in The Weekend?. J Amerta Nutr. 2018;2(4):307–16
  4. Kementrian Kesehatan Republik Indonesia. Laporan nasional riset kesehatan dasar (Riskesdas) Tahun 2018. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018:123-45, 580-2p
  5. Rahmawati A. Mekanisme terjadinya inflamasi dan stres oksidatif pada obesitas. El-Hayah. 2014;5(1):1–8
  6. Trapani, Laura, Valentina, Pallottini. Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective). Hindawi Publishing Corporation. 2010:1-7
  7. Corson M, Jones P, Davidson M. Review of the Evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. American Journal of Cardiology. 2008;101(12A):41F-50F
  8. Yardhika A, Alamanda M, Konny L. Pengukuran lipoprotein-associated phospholipase a 2 sebagai alat diagnostik dan penentu prognosis. 2017;8(1):31–4
  9. Nelson T, Kamineni A, Psatya B, Cushman M. Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia. 2011;54(2):329-3
  10. Hristov M, Weber C. Differential Role of Monocyte Subsets in Atherosclerosis. Thromb Haemost. 2011;106(5):757-62
  11. Shantsila E, Wrigley B, Tapp L, Apostolakis S. Immunophenotypic Characterization of Human Monocyte Subsets: Possible Implications for Cardiovascular Disease Pathophysiology. J Thromb Haemost. 2011;9(5):1056-66
  12. McIntyre TM PSSD. The emerging roles of PAF acetylhydrolase. J Lipid Res. 2009;50:S255-9
  13. Zhang Y. The economic costs of undiagnosed diabetes. Popul Health Manag. 2009;12(2):95-101
  14. Nurulita A, Bahrun U, Arif M. Perbandingan kadar apolipoprotein B dan fraksi lipid sebagai faktor risiko sindrom koroner akut. JST Kesehatan. 2011;1(1):94-100
  15. Burtis C, Ashwood E, Bruns D. Tietz Textbook of clinical chemistry and molecular diagnostics. 5th ed. United State of America: Elsevier Saunders; 2007:744
  16. Ma’rufi R RL. Hubungan dislipidemia dan kejadian penyakit jantung koroner. 2014;6(1):1–7
  17. Sachdeva A, Cannon CP, Deedwania PC, LaBresh KA, Smith SC, Dai D, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136.905 hospitalizations in get with the guidelines. Am Heart J 2009;157(1):111-17
  18. Madjid M, Ali M, Willerson JT. lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J 2010;37(1):25-39
  19. Masyarakat JK. Faktor-Faktor Yang Berhubungan Dengan Kejadian Obesitas Pada Karyawati Perusahaan Di Bidang Telekomunikasi Jakarta Tahun 2017. J Kesehat Masy. 2017;5(3):193–201
  20. Perkeni. Konsensus Pengelolaan Dislipidemia Di Indonesia. 1st ed. jakarta: Pusat Penerbitan Ilmu Penyakit Dalam FKUI; 2012
  21. Sakka S, Siahanidou T, Voyatzis C, Pervanidou P, Kaminioti C, Lazopoulou N, et al. Elevated circulating levels of lipoprotein- associated phospholipase A 2 in obese children. 2015;53(7):1119–25
  22. Da Silva IT, De Souza Timm A, Damasceno NRT. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: The healthy young cross-sectional study. Lipids Health Dis. 2013;12(1):1–8
  23. Adam JMF . Manfaat penurunan berat badan pada obese dengan komplikasi Metabolik. Dalam: R. Djokomoeljanto, Darmono,Tony Suhartono, TGD Pambayun editor. Naskah Lengkap Kongres Nasional V PERSADIA dan PIT PERKENI. Semarang: Badan Penerbit UNDIP;2002: 15-24
  24. Susilowati, R. Kadar Enzim Lp-PLA2 Serum Darah dan Jaringan Aorta pada berbagai Usia Tikus Wistar Jantan. Berk Penel Hayati Edisi Khusus. 2011;2:2007-9
  25. Collaboration PPS. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;1;375(9725):1536-44
  26. Stary HC, Chandler B, Dinsmore RE. A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis. American Heart Association; 1992;92(5):1355-74
  27. Maron DJ, Grundy SM, R, Pearson P. The Prevention of Coronary Heart Disease. In O’Rourke RA, editor. Hurst’s The Heart. 11th ed. New york: Mc.Graw Hill; 2009:1093-105
  28. Franeková J, Kettner J, Kubíček Z, Jabor A. The importance of age and statin therapy in the interpretation of Lp-PLA2 in ACS patients, and relation to CRP. Physiol Res. 2015;64(2):229–36
  29. Kaniawati M, Sukmawati IK, Manik TN. Hubungan antara Obesitas dengan Profil Kolesterol-LDL, Apolipoprotein B Dan Small Dense LDL pada Remaja. J Farm Galen. 2016;6(3)
  30. Elim C, C.Pangemanan DH, Supit S, Lindo V, Warouw SM. Gambaran Kadar Low Density Lipoprotein Pada Siswa-Siswi Overweight Dan Obesitas. J Biomedik. 2012;4:69–76
  31. Keavney B and Palmer A 2004. “Lipid related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk.” International Journal of Epidemiology. 2004;33(5):1002-1
  32. Bloom D, O’Neill FH, Marais AD. Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations. Clin Chem Lab Med. 2005;51:904-7
  33. Arsana PM, Rosandi R, Manaf A, Budhiarta A, Permana H, Sucipta KW, et al. Panduan pengelolaan dislipidemia di Indonesia. PB Perkeni, 2015
  34. Sniderman AD, Furberg CD, Keech A. Erratum: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment (Lancet (2003) 361 (777-780)). Lancet. 2003;362(9381):408
  35. Ballantyne CM, Raichlen JS, Cain VA. Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients. The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas. J Am Coll Cardiol. 2008;52(8):626–32
  36. Khan, M & Khaleel, M. Comparative Study of Serum Lipid Profile of Obese and Non-Obese Students (Male) of Aljouf University. International Journal of Biomedical and Advance Research. 2016;7(1): 035-037
  37. Aljaffar AGY. A Study of Serum Lipid Profile among Obese and Non-Obese Individuals: A Hospital based Study from Karbala, Iraq. Int J Contemp Med Res [IJCMR]. 2018;5(4):17–20
  38. Kanwar G, Kabra R. a Study of Association Between Obesity and Lipid Profile. Int J Res Applied, Nat Soc Sci. 2016;4(4):69–74
  39. Cholesterol Absorption, Synthesis, Metabolism, and Fate. In: Smith C, Marks A, Lieberman M. Mark’s Basic Medical Biochemistry (2nd edition). Philadelphia: Lippincott Williams & Wilkins, 2005:633-9
  40. Botham K, Mayes P. Sintesis, Transpor, dan Eskresi Kolesterol. In: Murray RK, Granner DK, Rodwell VW, editors. Biokimia Harper (27th ed). Pendit BU, alih bahasa. Jakarta: EGC, 2009:248-9

Last update:

No citation recorded.

Last update:

No citation recorded.